Noteworthy, among these vaccines are: Canvaxin, a vaccine composed of allogeneic irradiated tumor cells combined with BCG as an adjuvant [15]; VigilTM (FANGTM), a vaccine that included autologous tumor cells genetically modified to express GM-CSF [23] (NCT01453361); Melacine, an allogeneic tumor cell lysate vaccine that used MLPA as adjuvant [24], currently under investigation in combination with IFN-α in a phase III clinical trial (NCT00002767); and Vaccimel, a vaccine composed of allogeneic tumor-irradiated cells combined with BCG and GM-CSF as adjuvants [25]. This evidence concerns the gene CSF2 and neoplasm.